Analysis of retinal cellular infiltrate in experimental autoimmune uveoretinitis reveals multiple regulatory cell populations.
Experimental autoimmune uveoretinitis (EAU) is an animal model for human intraocular inflammatory disease. EAU is induced in B10.RIII mice by immunization with RBP-3 161-180 peptide and intraperitoneal pertussis toxin and is mediated by CD4(+) T cells that generate a clinically monophasic disease peaking approximately 2 weeks post-immunization. Collagenase digestion of retinal tissue allowed the quantification and characterization of leukocytes in the inflamed retina during disease progression. Using this method we identified three stages of disease. Initially there is a prodromal phase where we found significant changes in the number of leukocytes in the eye as early as 5 days post-immunization. This effect was, in part, non-antigen specific as a small increase in retinal leukocytes was also observed following immunization with OVA peptide. Following the prodrome there is a primary peak of infiltration including both CD4(+) T cells and CD11b(+) cells. This coincides with an early influx of neutrophils and is associated with a peak in IL-17-producing T cells. The neutrophils in the eye are CD11b(+) and Gr1(+) but can be distinguished from other myeloid cells by their high expression of Ly6G. The remaining CD11b(+)Gr1(+) cells can suppress proliferation and are analogous to myeloid derived suppressor cells which are found in tumors. The inflamed eye also contains a considerable proportion of FoxP3(+) regulatory cells. Following peak disease, the retina does not return to its pre-disease phenotype. Instead, fluctuations in infiltrating leukocyte numbers and changes to their relative composition continue, indicating that clinical recovery does not equate to the restoration of a normal retinal leukocyte population.
Kerr
Emma C
EC
Department of Cellular and Molecular Medicine, University of Bristol, School of Medical Sciences, University Walk, Bristol BS8 1TD, UK.
Raveney
Ben J E
BJ
Copland
David A
DA
Dick
Andrew D
AD
Nicholson
Lindsay B
LB
D000818:Animals; D000950:Antigens, Ly / Q000276:immunology / Q000378:metabolism; D001327:Autoimmune Diseases / Q000276:immunology / Q000473:pathology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D004195:Disease Models, Animal; D005136:Eye Proteins / Q000276:immunology; D006801:Humans; D020381:Interleukin-17 / Q000276:immunology; D051379:Mice; D022423:Myeloid Cells / Q000276:immunology; D009504:Neutrophils / Q000276:immunology; D037342:Pertussis Toxin / Q000494:pharmacology; D012160:Retina / Q000276:immunology / Q000473:pathology*; D012173:Retinitis / Q000276:immunology / Q000473:pathology*; D012177:Retinol-Binding Proteins / Q000276:immunology; D014605:Uveitis / Q000276:immunology / Q000473:pathology*; D000099214:Retinol-Binding Proteins, Interstitial
D000950:Antigens, Ly; D005136:Eye Proteins; D020381:Interleukin-17; D037342:Pertussis Toxin; D012177:Retinol-Binding Proteins; D000099214:Retinol-Binding Proteins, Interstitial; C480309:Ly6G antigen, mouse